

The University of the Pacific LAW REVIEW



Volume 51

Issue 3

2020

ARTICLES

- | | | |
|--|-----|---|
| <i>Introduction: Changing Regulation of Pharmaceuticals: Issues in Pricing, Intellectual Property, Trade and Ethics</i> | 447 | <i>Michael S. Mireles</i> |
| <i>WTO Law and Prices of Pharmaceutical Products: Rule of Law Gaps and the Unclear Balance between Trade Protection, Human Rights, and IP Protection</i> | 451 | <i>Henrik Andersen</i> |
| <i>The Pharmaceutical Industry's Corrupt Price Discrimination System: A Single Solution?</i> | 475 | <i>Samuel F. Ernst</i> |
| <i>Congress Should Decline Ill-Advised Legislative Proposals Aimed at Evergreening of Pharmaceutical Patent Protection</i> | 493 | <i>Christopher M. Holman</i> |
| <i>Reconsidering the Rationale for the Duration of Data Exclusivity</i> | 525 | <i>Jonathan Kimball, Srividhya Ragavan & Sophia Vegas</i> |
| <i>The Biosimilar Action Plan: An Effective Mechanism for Balancing Biologic Innovation and Competition in the United States?</i> | 539 | <i>Simone Rose & Tracea Rice</i> |
| <i>Patents & Legal Expenditures</i> | 577 | <i>Christopher J. Ryan, Jr. & Brian L. Frye</i> |
| <i>China's Innovative Turn and the Changing Pharmaceutical Landscape</i> | 593 | <i>Peter K. Yu</i> |